Ignyta (Ignyta) Debt-to-Asset : 0.19 (As of Sep. 2017)

View and export this data going back to 2014. Start your Free Trial

What is Ignyta Debt-to-Asset?

Ignyta's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2017 was $0.00 Mil. Ignyta's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2017 was $29.99 Mil. Ignyta's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Sep. 2017 was $154.37 Mil. Ignyta's debt to asset for the quarter that ended in Sep. 2017 was 0.19.

Ignyta Debt-to-Asset Historical Data

The historical data trend for Ignyta's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ignyta Debt-to-Asset Chart

Ignyta Annual Data

Trend

Aug12

Aug13

Dec14

Dec15

Dec16

Debt-to-Asset

0.24

0.21

0.22

Ignyta Quarterly Data
	Nov12	Feb13	May13	Aug13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17
Debt-to-Asset	Get a 7-Day Free Trial															0.29	0.22	0.26	0.17	0.19

Competitive Comparison of Ignyta's Debt-to-Asset

For the Biotechnology subindustry, Ignyta's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ignyta's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ignyta's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Ignyta's Debt-to-Asset falls into.

Ignyta Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Ignyta's Debt-to-Asset for the fiscal year that ended in Dec. 2016 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0	+	31.117)	/	144.914
	=	0.21

Ignyta's Debt-to-Asset for the quarter that ended in Sep. 2017 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0	+	29.994)	/	154.365
	=	0.19

Ignyta (NAS:RXDX) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Ignyta Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Ignyta's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Ignyta (Ignyta) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ignyta Inc (NAS:RXDX) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.ignyta.com

Ignyta is an oncology biotechnology company. Its research is targeting tumor reduction and cancer treatment through both integrated therapeutic and companion diagnostics. The integrated therapeutic segment aims to discover, develop, and commercialize molecularly targeted therapies. The companion diagnostic segment aims to pair the discovered therapies with biomarker-based companion diagnostics to precisely identify, at the molecular level, patients likely to have good results. The company's portfolio includes compounds to treat adult patient populations for solid tumors, pediatric patients with advanced solid tumor malignancies, and patients with superficial and nodular basal cell carcinoma.

Executives

James L Freddo	director	3115 MERRYFIELD ROW, SAN DIEGO CA 92121
Steven L. Hoerter	director	C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451
Pratik S Multani	officer: Chief Medical Officer	C/O FATE THERAPEUTICS, INC., 3535 GENERAL ATOMICS COURT, SUITE 200, SAN DIEGO CA 92121
Jonathan E Lim	director, 10 percent owner, officer: President, CEO & Director	11588 SORRENTO VALLEY ROAD, SUITE 17, SAN DIEGO CA 92121
Heinrich Dreismann	director	320 WAKARA WAY, SALT LAKE CITY UT 84108
Jacob Chacko	officer: Chief Financial Officer	C/O IGNYTA, INC., 11095 FLINTKOTE AVE., SUITE D, SAN DIEGO CA 92121
Igor Bilinsky	officer: GM, Immuno-Oncology/SVP Sp Ops	C/O VICAL INCORPORATED, 10390 PACIFIC CENTER COURT, SAN DIEGO CA 92121
Matthew Onaitis	officer: General Counsel and Secretary	C/O SOMAXON PHARMACEUTICALS, INC., 10935 VISTA SORRENTO PARKWAY, SUITE 250, SAN DIEGO CA 92130
Adrian Senderowicz	officer: Chief Medical Officer	C/O PUMA BIOTECHNOLOGY, INC., 10880 WILSHIRE BOULEVARD, SUITE 2150, LOS ANGELES CA 90024

Ignyta (Ignyta) Headlines

From GuruFocus

Steven Cohen Dives Deeper Into Health Care

By Graham Griffin Graham Griffin • 03-23-2021